Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

Keeping track of the T cells that matter

Nature Cancer volume 3, pages 1015–1017 (2022)Cite this article

Subjects

The identification of tumor-reactive T cells using phenotypic markers is now well established in treatment-naive tumors. It is unclear, however, whether these markers can also be useful after immune checkpoint blockade (ICB). A new study finds that CXCL13 expression robustly identifies tumor-reactive T cells before and after ICB and is associated with treatment response.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: CXCL13+ tumor-reactive CD8+ T cells in human cancers at baseline and following immune checkpoint blockade.

References

  1. Liu, B., Zhang, Y., Wang, D., Hu, X. & Zhang, Z. Nat. Cancer https://doi.org/10.1038/s43018-022-00433-7 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Gros, A. et al. Nat. Med. 22, 433–438 (2016).

    Article  CAS  Google Scholar 

  3. Scheper, W. et al. Nat. Med. 25, 89–94 (2019).

    Article  CAS  Google Scholar 

  4. Tran, K. Q. et al. J. Immunother. 31, 742–751 (2008).

    Article  CAS  Google Scholar 

  5. Simoni, Y. et al. Nature 557, 575–579 (2018).

    Article  CAS  Google Scholar 

  6. Duhen, T. et al. Nat. Commun. 9, 2724 (2018).

    Article  Google Scholar 

  7. Thommen, D. S. et al. Nat. Med. 24, 994–1004 (2018).

    Article  CAS  Google Scholar 

  8. Oliveira, G. et al. Nature 596, 119–125 (2021).

    Article  CAS  Google Scholar 

  9. Lowery, F. J. et al. Science 375, 877–884 (2022).

    Article  CAS  Google Scholar 

  10. Caushi, J. X. et al. Nature 596, 126–132 (2021).

    Article  CAS  Google Scholar 

  11. Litchfield, K. et al. Cell 184, 596–614.e14 (2021).

    Article  CAS  Google Scholar 

  12. Zhang, Y. et al. Cancer Cell 39, 1578–1593.e8 (2021).

    Article  CAS  Google Scholar 

  13. van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. Nat. Rev. Cancer 20, 218–232 (2020).

    Article  Google Scholar 

  14. Garcia-Diaz, A. et al. Cell Rep. 19, 1189–1201 (2017).

    Article  CAS  Google Scholar 

  15. David, J. M. et al. Oncoimmunology 6, e1349589 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    Paulien Kaptein & Daniela S. Thommen

Authors
  1. Paulien Kaptein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela S. Thommen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniela S. Thommen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaptein, P., Thommen, D.S. Keeping track of the T cells that matter. Nat Cancer 3, 1015–1017 (2022). https://doi.org/10.1038/s43018-022-00432-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00432-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer